Viewing Study NCT02290951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2026-02-25 @ 12:57 AM
Study NCT ID: NCT02290951
Status: COMPLETED
Last Update Posted: 2025-10-10
First Post: 2014-11-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Sponsor: Regeneron Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Hodgkin Lymphoma View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Diffuse large B-cell lymphoma (DLBCL) View
None Follicular lymphoma (FL) View
None Aggressive lymphoma View